Skip to main content
Top
Published in: Trials 2/2015

Open Access 01-12-2015 | Poster presentation

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials

Authors: Graham Wheeler, Michael Sweeting, Adrian Mander

Published in: Trials | Special Issue 2/2015

Login to get access

Excerpt

Phase I trials of anti-cancer therapies aim to identify a Maximum Tolerated Dose (MTD), defined as the dose that causes unacceptable toxicity in a target proportion of patients. In such trials, the dose given to patients is adapted as dose-response data are accrued and the next patient may receive a higher, lower, or identical dose to that of previous patients. …
Metadata
Title
A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials
Authors
Graham Wheeler
Michael Sweeting
Adrian Mander
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Trials / Issue Special Issue 2/2015
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-16-S2-P233

Other articles of this Special Issue 2/2015

Trials 2/2015 Go to the issue